Analytical Data
-
Gene name
MYEOV
- Application
-
Alternative Names
Myeloma-overexpressed gene protein; MYEOV; MYEOV_HUMAN; OCIM; Oncogene in multiple myeloma
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q96EZ4
-
Expression Region
1-313 aa
-
AA Sequence
MALRICVTYT PALPIGLCTR CCLCLEQSPS WCHCLRGVSF LTFHLHQSVP LGDRDSLLMF TRQAGHFVEG SKAGRSRGRL CLSQALRVAV RGAFVSLWFA AGAGDRERNK GDKGAQTGAG LSQEAEDVDV SRARRVTDAP QGTLCGTGNR NSGSQSARVV GVAHLGEAFR VGVEQAISSC PEEVHGRHGL SMEIMWARMD VALRSPGRGL LAGAGALCMT LAESSCPDYE RGRRACLTLH RHPTPHCSTW GLPLRVAGSW LTVVTVEALG GWRMGVRRTG QVGPTMHPPP VSGASPLLLH HLLLLLLIII LTC
-
Molecular Weight
33.5 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
MYEOV (myeloma overexpressed protein) is a protein that has garnered attention in cancer research due to its upregulation in multiple myeloma and other malignancies. Identified as a potential biomarker, MYEOV is implicated in tumorigenesis and cellular proliferation, making it a candidate for targeted therapies and diagnostics. Previous studies have suggested that MYEOV may interact with critical oncogenic pathways, influencing cell survival and proliferation, thus contributing to the aggressive nature of certain cancers. Researchers are focusing on recombinantly expressing MYEOV to understand its functionality, interactions, and potential as a therapeutic target. By producing a recombinant version of MYEOV, scientists aim to investigate its structural properties and biological roles in greater detail, which could lead to novel interventions for cancer treatment. Additionally, understanding MYEOV's mechanisms at the molecular level may provide insights into its potential role in other diseases, further emphasizing its significance in biomedical research. This ongoing investigation into MYEOV not only highlights the importance of protein research in cancer biology but also reflects the broader quest for innovative approaches to combat complex diseases through targeted therapies.
